Objective To investigate the potential mechanism of microRNA(miRNA)in hepatitis B virus(HBV)infection.Methods The peripheral blood samples were collected from four chronic hepatitis B(CHB)patients who visited Mengchao...Objective To investigate the potential mechanism of microRNA(miRNA)in hepatitis B virus(HBV)infection.Methods The peripheral blood samples were collected from four chronic hepatitis B(CHB)patients who visited Mengchao Hepatobiliary Hospital of Fujian Medical University in 2017,and those were also collected from four healthy controls.Affymetrix GeneChip microRNA 4.0 was applied to detect the expressions of miRNA between CHB patients and healthy controls.展开更多
文摘目的探讨HBV相关慢加急性肝衰竭(HBV-ACLF)患者发生细菌感染的危险因素并构建预测模型。方法回顾性分析2015年1月至2018年12月福建医科大学孟超肝胆医院收治的255例HBV-ACLF患者的临床资料,包括患者确诊肝衰竭2 d内(基线)的临床资料及并发症,将住院期间发生细菌感染做为临床结局事件。采用R语言进行数据分析和列线图制作,用lasso回归和logistic回归筛选和分析危险因素,并构建预测模型;采用受试者工作特征曲线下面积(AUC)和校正曲线分析模型的预测效能并通过Bootstrap法对模型进行内部验证。结果255例HBV-ACLF患者中,男198例,住院期间发生细菌感染203例(79.60%)。lasso回归分析以lambda=lambda.1 se(0.049)为标准,共筛选出年龄、基线直接胆红素(DBil)、胆碱酯酶(CHE)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、C-反应蛋白(CRP)和肝性脑病(HE)等7个变量为并发细菌感染的相关危险因素,并进一步构建logistic回归模型,回归方程为logistic(p)=-7.1733+0.0495×AGE+0.4107×ln(DBil)-0.0002×CHE+0.0350×PT+0.0610×APTT+0.5212×ln(CRP)+1.3582×(HE=1 or 0),其中年龄(OR=1.05,95%CI:1.02~1.09,P=0.0025)、DBil(OR=1.51,95%CI:1.06~2.17,P=0.0230)、CRP(OR=1.68,95%CI:1.11~2.62,P=0.0161)和HE(OR=3.88,95%CI:1.37~14.10,P=0.0193)为独立危险因素。模型的特异度为84.62%,灵敏度为69.49%。新建预测模型的诊断效能(AUC=0.851)优于CRP(AUC=0.719)和降钙素原(AUC=0.655)。结论HBV-ACLF患者的年龄越大、基线高DBil血症、低CHE水平、PT延长、APTT延长、CRP升高和发生HE,发生细菌感染风险高;根据这7项危险因素构建的模型对HBV-ACLF患者住院后并发细菌感染事件具有良好的预测效能。
文摘Objective To investigate the potential mechanism of microRNA(miRNA)in hepatitis B virus(HBV)infection.Methods The peripheral blood samples were collected from four chronic hepatitis B(CHB)patients who visited Mengchao Hepatobiliary Hospital of Fujian Medical University in 2017,and those were also collected from four healthy controls.Affymetrix GeneChip microRNA 4.0 was applied to detect the expressions of miRNA between CHB patients and healthy controls.